Literature DB >> 1970300

Comparison of bopindolol and atenolol in chronic stable angina pectoris.

P Fitscha1, W Meisner, B Tiso.   

Abstract

The efficacy of bopindolol and atenolol in the treatment of patients with chronic stable angina pectoris have been compared in a double blind, randomized study. Both bopindolol 1 mg and atenolol 100 mg for 6 weeks increased mean exercise time (25% and 22%, respectively, compared to placebo), time to angina (27% and 25%), and time to 1 mm of ST-segment depression (32% and 20%). Both drugs reduced ST-segment depression similarly at maximal and submaximal work levels. There was no significant difference in their antianginal efficacy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970300     DOI: 10.1007/bf00314809

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  The pharmacology of atenolol.

Authors:  A M Barrett
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

2.  Celiprolol in angina pectoris: a controlled study.

Authors:  J Eff; J Godfrey; R Garutti; P Capone
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

3.  Comparison of the acute haemodynamic effects of bopindolol and propranolol at rest and during supine exercise.

Authors:  P Fitscha; W Meisner; B Tiso
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Atenolol in the treatment of angina pectoris.

Authors:  J Erikssen; K Osvik; J Dedichen
Journal:  Acta Med Scand       Date:  1977

5.  Long-term benefit of cardioselective beta blockade with once-daily atenolol therapy in angina pectoris.

Authors:  J B Schwartz; G Jackson; R E Kates; D C Harrison
Journal:  Am Heart J       Date:  1981-04       Impact factor: 4.749

6.  Assessment of metoprolol, a cardioselective beta-blocking agent, during chronic therapy in patients with angina pectoris.

Authors:  J S Borer; M B Comerford; E Sowton
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

7.  Bopindolol: a new long acting beta-receptor antagonist; its effects on haemodynamics, and on the renin response to tilting.

Authors:  D R Turner; F J Goodwin; A R Knight; D W Littlejohns; V L Sharman; D W Vere
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

8.  Comparison of carvedilol and atenolol for angina pectoris.

Authors:  S B Freedman; S M Jamal; P J Harris; D T Kelly
Journal:  Am J Cardiol       Date:  1987-09-01       Impact factor: 2.778

9.  Influence of atenolol and bopindolol on circadian heart rate.

Authors:  P Fitscha; W Meisner; B Tiso
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

  9 in total
  1 in total

Review 1.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.